GSK (LSE:GSK) shares ended 2024 on a bitter notice after what proved to be a rollercoaster 12 months.

The pharma large dropped 7% over the 12 months, as worries over Zantac litigation and potential shake-ups in US healthcare coverage shook investor confidence.

But the underlying well being of the FTSE 100 agency has remained steadfast, as illustrated by spectacular full-year outcomes launched immediately (5 February).

GSK’s share price has spiked 5% following the information. Can it maintain going?

Forecasts overwhelmed

Helped by what it described as “accelerating momentum in Specialty Medicines“, full-year revenues at GSK rose 7% at fixed currencies to £31.4bn. This beat dealer consensus estimates by round £300m.

Turnover was up 4% at precise trade charges.

GSK mentioned that “continued growth across disease areas” pushed Specialty Drugs gross sales 19% increased at secure currencies, to £11.8bn. Oncology was the standout right here, with revenues nearly doubling 12 months on 12 months on the identical foundation (up 98%).

Power right here greater than offset a 4% gross sales decline on the agency’s Vaccines division. Turnover dropped as stricter age guidelines within the US for respiratory syncytial virus (RSV) therapy triggered Arexvy gross sales to plummet 51%.

At group degree, GSK’s working revenue dropped 33% and 40% at precise and fixed currencies, respectively, to £4bn. It mirrored a £1.8bn cost because the enterprise settled US claims that its Zantac heartburn drug triggered most cancers.

Core working revenue, which strips out these litigatory headwinds, rose 11% from 2023 ranges.

Sturdy momentum

GSK’s on a roll in the intervening time. Following a collection of steerage upgrades final 12 months, it’s acquired 2025 off to a bang and is anticipating one other 12 months of stable progress.

The Footsie agency expects turnover to rise between 3% and 5% at fixed currencies, and core working revenue to advance between 6% and eight%.

GSK additionally hiked its 2031 gross sales goal, which it mentioned mirrored “late-stage pipeline progress”. Turnover is now tipped at £40bn, a £2bn improve from prior targets.

In the present day, the corporate has 71 Specialty Medicines and Vaccines in medical improvement. Of those, 19 are on the Part III testing or registration phases.

GSK additionally confirmed it expects 5 “major” new product approvals in 2025, together with Blenrep (which tackles a number of myeloma) and Depemokimab (for extreme bronchial asthma).

What subsequent?

Investing in pharma shares like this may be dicey enterprise at instances. As GSK witnessed final 12 months with Arexy, modifications to the regulatory surroundings could cause havoc amongst sure product strains.

On prime of this, growing medicines is very advanced and due to this fact unpredictable. Setbacks and the testing or registration phases can, by way of a mix of gross sales points and further prices, go away earnings forecasts in tatters.

However as immediately’s replace exhibits, GSK’s making spectacular strides despite the fact that these threats stay. Certainly, its sturdy document of pipeline execution stays extremely encouraging, the enterprise having fun with round a dozen optimistic late stage medical updates in 2024 alone.

Its plans to develop into a powerhouse within the fields of respiratory, HIV and oncology remedies stay nicely on observe.

Regardless of immediately’s rise, GSK’s shares nonetheless look low-cost in comparison with these of its trade friends. Its ahead price-to-earnings (P/E) ratio is a modest 10.2 instances.

Whereas nothing is assured, I’m optimistic that GSK’s low valuation and spectacular momentum might result in extra spectacular share price beneficial properties. I feel it’s a prime FTSE 100 inventory to think about.